OncoMatch/Clinical Trials/NCT05133882
A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML
Is NCT05133882 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Clifutinib Besylate for acute myeloid leukemia, adult.
Treatment: Clifutinib Besylate — This is a multi-center open clinical study aimed at evaluating the efficacy and safety of Clifutinib Besylate combined with chemotherapy in newly-treated adult subjects with AML
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 ITD
the extension phase requires the subject to be positive for the FLT3-ITD mutation
Excluded: BCR ABL fusion
BCR-ABL positive leukemia
Prior therapy
Cannot have received: FLT3 inhibitor
previously received FLT3 inhibitor
Cannot have received: chemotherapy or radiotherapy for other tumors
Diagnosed as secondary to AML due to previous chemotherapy or radiotherapy of other tumors
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05133882 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require FLT3?
Yes, FLT3 ITD is a required biomarker for enrollment.
Are patients with BCR alterations eligible?
No. BCR ABL fusion is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages